Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles including a data breach.

23andMe will keep offering customers its DNA testing services after being bought out of bankruptcy. New York-based biotech company Regeneron Pharmaceuticals announced an agreement on Monday to purchase the 23andMe startup for $256 million, alongside its Total Health and Research Services business and biobank of customer data and genetic samples.

What happened to 23andMe? Here's a look at its history from launch to bankruptcy and acquisition by Regeneron.